Table 2.
Sample Characteristics Upon Admission
| N | Mean | Median | SD | Minimum | Maximum | |
|---|---|---|---|---|---|---|
| Age | 42 | 28.7 | 27 | 7.9 | 18 | 52 |
| BMI (kg/m2) | 38 | 22 | 22 | 3 | 17 | 35 |
| CRP (mg/dL) | 26 | 4.9 | 1.9 | 8 | 0.20 | 35 |
| ALT (IU/L) | 42 | 23 | 19.5 | 11.8 | 8 | 158 |
| Renal laboratory | ||||||
| eGFR (mL/min) | 42 | 104.4 | 105.7 | 13.5 | 78.8 | 126.8 |
| Creatinine (mg/dL) | 42 | 0.93 | 0.94 | 0.14 | 0.71 | 1.25 |
| Cannabis dependence/history and nicotine | ||||||
| Number of dependence criteria (ICD-10) | 42 | 4.14 | 4 | 0.35 | 4 | 5 |
| Duration of ICD-10-cannabis dependence (years) | 42 | 10 | 7 | 6.7 | 3 | 32 |
| Daily cannabis use (g/day) | 42 | 2.5 | 2.5 | 1.2 | 0.5 | 6 |
| Duration of prior daily cannabis use (months) | 42 | 55 | 36 | 62 | 6 | 360 |
| Number of daily cigarettes | 42 | 22.4 | 20 | 6.5 | 5 | 40 |
| Serum cannabinoid levels | ||||||
| THC (ng/mL) | 36 | 13.4 | 7.2 | 23.2 | 0.1 | 139.7 |
| THC-OH (ng/mL) | 37 | 4.1 | 1.6 | 7.9 | 0.1 | 50 |
| THC-COOH (ng/mL) | 37 | 151.1 | 112.9 | 149.7 | 6.9 | 741.4 |
| Psychometry (points) | ||||||
| MWC | 41 | 6.4 | 6 | 2.7 | 2 | 13 |
| MWC-2 | 41 | 8.7 | 10 | 3.4 | 2 | 16 |
| CGI-Severity | 41 | 4 | 4 | 0.6 | 2 | 5 |
| HAMD | 38 | 8.9 | 8 | 6.5 | 1 | 30 |
| HAMA | 38 | 9.5 | 7.5 | 6.8 | 2 | 30 |
ALT, alanine aminotransferase; BMI, body mass index; CGI-Severity, Clinical Global Impression-Severity-Score; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HAMA, Hamilton Anxiety Rating Scale; HAMD, Hamilton Depression Rating Score; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Revision 10; MWC, Marihuana Withdrawal Checklist upon admission; MWC-2, Marihuana Withdrawal Checklist at day 2 postadmission; SD, standard deviation; THC, Δ-9-tetrahydrocannabinol; THC-COOH, 11-Nor-9-carboxy-Δ-9-tetrahydrocannabinol; THC-OH, 11-Hydroxy-Δ-9-tetrahydrocannabinol.